The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Pharmacyclics Inc

Nasdaq: PCYC
Last

(U.S.) $131.45

Today's change-1.89 -1.42%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Pharmacyclics Inc

Nasdaq: PCYC
Last

(U.S.) $131.45

Today's change-1.89 -1.42%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Pharmacyclics Inc down (U.S.)$1.89

Pharmacyclics Inc closed lower Friday, dropping (U.S.)$1.89 or 1.42% to (U.S.)$131.45. Shares have lost 0.90% over the last five days, but have gained 24.27% over the last year to date. This security has outperformed the S&P 500 by 15.20% during the last year.

Key company metrics

  • Open(U.S.) $133.40
  • Previous close(U.S.) $133.34
  • High(U.S.) $133.40
  • Low(U.S.) $129.21
  • Bid / Ask-- / --
  • YTD % change+24.27%
  • Volume2,703,753
  • Average volume (10-day)833,398
  • Average volume (1-month)669,541
  • Average volume (3-month)746,932
  • 52-week range(U.S.) $82.51 to (U.S.) $154.89
  • Beta0.70
  • Trailing P/E120.46×
  • P/E 1 year forward156.81×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $1.09
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+15.43%

Based on its net profit margin of 15.43%, Pharmacyclics Inc is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue207113119124
Total other revenue--------
Total revenue207113119124
Gross profit196104113120
Total cost of revenue12964
Total operating expense15915010138
Selling / general / administrative38453540
Research & development44463545
Depreciation / amortization00----
Interest expense (income), net operating--------
Unusual expense (income)655025--
Other operating expenses, total0-----50
Operating income48-371885
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax48-371885
Income after tax41-371864
Income tax, total70021
Net income41-371864
Total adjustments to net income--------
Net income before extra. items41-371864
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items41-371864
Inc. avail. to common incl. extra. items41-371864
Diluted net income41-371864
Dilution adjustment--0----
Diluted weighted average shares78757878
Diluted EPS excluding extraordinary itemsvalue per share0.53-0.490.230.82
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share1.24-0.060.440.82